Hypothalamic Diseases  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
NCT00958841 / 2008-007348-32: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Terminated
2
118
US, Canada, Europe, RoW
pasireotide LAR, SOM230
Novartis Pharmaceuticals
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
06/15
06/15
Passion I, NCT01283542: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

Completed
2
20
RoW
Pasireotide LAR
Novartis Pharmaceuticals
Non-functioning Pituitary Adenoma
09/17
09/17

Download Options